Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
about
Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agentsCrohn's disease and skinReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseNew insights into the dichotomous role of innate cytokines in gut homeostasis and inflammationBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsManagement of active Crohn disease.A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.Alopecia secondary to anti-tumor necrosis factor-alpha therapyBody image dissatisfaction in patients with inflammatory bowel disease.Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities.Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.Two Cases of Paradoxical Hidradenitis Suppurativa while on AdalimumabInfliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response.Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies.Successful treatment of localized pyoderma faciale in a patient with Crohn's disease.The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.Treatment of extraintestinal manifestations in inflammatory bowel disease.Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.Targeting TNF-α for the treatment of inflammatory bowel disease.Certolizumab pegol in axial spondyloarthritis.Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Certolizumab pegol for the treatment of psoriasis.TNF-inhibitor associated psoriatic alopecia: Diagnostic utility of sebaceous lobule atrophy.Paradoxical Side Effect Related With Anti-Tumor Necrosis Factor Alpha Treatment.Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash.Skin Manifestations of Inflammatory Bowel Disease.Crohn's disease diagnosis during adalimumab treatment.Digestive system in psoriasis: an update.Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
P2860
Q22305935-9A6648B4-C16E-4C6A-B443-9108E737F0DDQ26752869-634CE6CB-9E6A-469A-81DF-5A0855238C11Q26822029-7A317E20-7535-46A0-A206-2099BD357C0AQ26823773-52195ACB-DF22-4478-9619-0046C7EA73EDQ26999078-6B5FA708-C490-4A32-91F0-D99A22533F1EQ34345967-30A82413-677E-42CE-8F74-7DF8219CE013Q35100143-576F5591-E837-4513-8E79-AF6D1F5A5E88Q35211826-A0952048-A600-4685-8AC2-BFB2D9273D70Q35216581-5BEE7898-1893-4423-8CF7-6C144FC4E767Q36552806-1C8F82E6-924E-4970-BF76-755B9C4D5A3AQ36586054-B45BD84C-EDE3-4504-9527-7C3A261C5C95Q37057086-E601BC88-E634-4DA8-BE9B-25B7365D9E00Q37329074-2AECE364-51CD-41EA-9498-537D4FB0B461Q37432287-331A4B1F-1181-4A1E-8D9D-CF3D916876ECQ37693869-314A573C-834B-48F0-A9E3-5D9FD3282C51Q38024281-EA666405-BD3B-49D6-B729-E968C4EB187EQ38034394-583B892E-397E-47A2-906A-D10E999215CBQ38050884-7D40E31E-686C-4A69-A338-DCFF7987F8C0Q38050938-11E2E7A1-26E6-4EF3-8EFC-F64C322D2E61Q38160905-56BB0EE9-B65E-446C-B575-031B9AE4334EQ38161555-2E8335EF-49B1-4290-9289-A5923162F4CDQ38179468-B5534ADC-43FD-4546-90C8-83A3CFF002EAQ38315640-22D6CF5E-7DCC-47A3-89B5-06C0263EC095Q38707864-C58953C2-9C54-4701-BFF8-E02FD6B25FC9Q38976796-0D769D2F-0FA2-4551-BCF8-8A1F7B9EF063Q39195227-88F6F8C8-851D-4BCE-BC6C-90580A21F1EEQ40101338-284BDAFA-F706-4FE5-BED4-1F57C8A4E0C7Q40791552-78AEEF57-FA67-4CB5-9559-5C16F1D52C1DQ40792685-8EB862BE-DE3C-4979-AC68-7A56A62C6408Q41520678-6D95D54E-6794-4484-8AD6-3BF7749BC54FQ42074843-0250FA3E-4093-46C6-A48B-2AD5D7541B99Q44390503-D8BCCE8A-C92F-4ECA-8BD0-E7D6CC9A4B6DQ45050734-7E95749F-20C3-4773-B81B-D58F675ACDDBQ46466020-71066D72-79DE-4D23-B556-BFA2FE71DD5AQ48102896-EF7C3191-BBC8-4C7D-8621-713EE5D586A4Q49970991-F2E30781-7C3E-411A-BCD1-2E6473F05382Q50439934-0E16AF18-FC8B-44D0-A9F7-5D0937E7F870Q50681708-C9D1B404-8EC6-4B14-8B9F-6946BF865971Q51136025-3B819083-3A0E-40F8-92DD-C71BF8D0EA05Q51565778-07DCBDB2-F770-4AA7-A79C-5739CF782A03
P2860
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Psoriasis associated with anti ...... 120 cases from the literature.
@en
Psoriasis associated with anti ...... 120 cases from the literature.
@nl
type
label
Psoriasis associated with anti ...... 120 cases from the literature.
@en
Psoriasis associated with anti ...... 120 cases from the literature.
@nl
prefLabel
Psoriasis associated with anti ...... 120 cases from the literature.
@en
Psoriasis associated with anti ...... 120 cases from the literature.
@nl
P2093
P1476
Psoriasis associated with anti ...... 120 cases from the literature.
@en
P2093
A S Cheifetz
D Kroshinsky
J R Korzenik
P304
P356
10.1111/J.1365-2036.2011.04866.X
P407
P577
2011-09-29T00:00:00Z